Skip to main content
. Author manuscript; available in PMC: 2020 Oct 2.
Published in final edited form as: Cell Rep. 2020 Sep 1;32(9):108080. doi: 10.1016/j.celrep.2020.108080

Figure 2. Progression of the Irradiated Tumor Cells through Mitosis Is Required for Systemic Anti-tumor Immune Responses.

Figure 2.

(A) Scheme showing B16 melanoma model. Created with BioRender.

(B and C) Growth of WT B16 cells (untreated tumors) after injection of B16 WT cells with no treatment, 10-Gy irradiation, or 10-Gy irradiation with CDK1i treatment (B), and WT B16 cells or Ku70 KO B16 cells with no treatment or 10-Gy irradiation (C) 3 days before implantation, respectively. All mice were administrated with anti-CTLA-4 antibody (9H10) as described in (A). Animal numbers are indicated in parentheses of treatment groups.

(D and E) Statistic of tumor volumes at day 15 as measured in (B) and (C). Statistical significance is compared using a two-tailed t test. Error bars are SEM of biological replicates.